Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics.

Abstract

Pazopanib has a manageable safety profile in patients with advanced HCC, and 600 mg was chosen for further development of pazopanib in advanced HCCs. Moreover, pazopanib reduced tumor vessel leakage, as shown by DCE-MRI, indicating a direct effect on HCC vasculature that might be associated with its antitumor activity.

Full Text

• DOI - Clinical cancer research : an official journal of the American Association for Cancer Research (DOI)
• HighWire Press - full-text online

Subjects

• Adult
• Aged
• Angiogenesis Inhibitors
• Carcinoma, Hepatocellular
• Disease-Free Survival
• Dose-Response Relationship, Drug
• Female
• Humans
• Liver Neoplasms
• Male
• Middle Aged
• Pyrimidines
• Sulfonamides
• alpha-Fetoproteins

Similar articles

• Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. (2012-11-16)
• An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer. (2013-02-28)
• Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib. (2012-11-08)
• Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. (2012-10-06)
• Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal. (2013-01-18)
• A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. (2013-01-12)
• Pazopanib as Second-Line Treatment After Sunitinib or Bevacizumab in Patients With Advanced Renal Cell Carcinoma: A Sarah Cannon Oncology Research Consortium Phase II Trial. (2013-05-09)
• The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. (2011-11-02)
• A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. (2010-11-18)

Authors

• Thomas Yau
• Pei-Jer Chen
• Pierre Chan
• C Martin Curtis
• Philip S Murphy
• A Benjamin Suttle
• Jennifer Gauvin
• Jeffrey P Hodge
• Mohammed M Dar
• Ronnie T Poon

Publication date

2011-11-02

Journal

Journal topics

• Neoplasms

Language

Eng.

Copyright

Clinical cancer research : an official journal of the American Association for Cancer Research

Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.

Release reference

Clin Cancer Res. 2011 Nov;17(21):6914-23

Related books

• Books of Angiogenesis Inhibitors
• Books of Carcinoma, Hepatocellular
• Books of Disease-Free Survival
• Books of Dose-Response Relationship, Drug
• Books of Liver Neoplasms
• Books of Neoplasms
• Books of Pyrimidines
• Books of Sulfonamides
• Books of alpha-Fetoproteins